AbbVie Inc. (ABBV): Revenue
$61.16B
Year ended 2025-12-31
$64.39B
Trailing 12 months to 2026-06-30
+1.8%
3-year compound annual growth
+6.0%
5-year compound annual growth
+10.3%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.16B | +8.6% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $56.33B | +3.7% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $54.32B | -6.4% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $58.05B | +3.3% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $56.20B | +22.7% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $45.80B | +37.7% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $33.27B | +1.6% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $32.75B | +16.1% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $28.22B | +10.1% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $25.64B | +12.2% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $22.86B | +14.5% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $19.96B | +6.2% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $18.79B | +2.2% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $18.38B | +5.4% | 2015-02-20, From 2012-01-01 |
| 2011-12-31 | $17.44B | n/a | 2014-02-21, From 2011-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $61.16B | +8.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $17.26B | +4.3% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $14.34B | +1.0% |
Compare ABBV, PFE, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗